Navigation Links
Rituxan in Medical News

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...s in the present day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as rituxan and Orencia made significant inroads by addressing therapeutic needs not addressed by existing drugs. The global marketplace is characterized by p...

City of Hope Uses Isilon IQ to Advance Fight Against Life-Threatening Diseases

...dical breakthroughs, including the first synthetic human insulin and human growth hormone, as well as the widely used cancer fighting drugs Herceptin, rituxan and Avastin. Working with leading Isilon value-added systems integrator Talon Data Systems, City of Hope has deployed Isilon IQ to centralize e...

Cancer Drug May Offer New Hope for Lupus Patients

... Small U.K. study says rituxan could become 1st new drug for disease in 50 years ...IDAY, March 13 (HealthDay News) -- The cancer drug rituxan may offer the first new treatment approved for lup...y low levels of albumin protein in their blood. rituxan targets hyperactive B cells, which contribute to k...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

...ith other mechanisms of action, such as Orencia and Biogen Idec/Genentech's rituxan (also marketed by Chugai and Zenyaku Kogyo in Japan, and marketed as MabThe...orts, only one percent of surveyed rheumatologists reported that Orencia or rituxan was the first brand that came to mind when thinking of rheumatoid arthritis...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...y available therapies that include Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux, Genentech/Biogen Idec/Chugai's rituxan / Roche's MabThera. The new Pharmacor report entitled Antibody Therapies in Oncology finds that the major driving force behind market growth of the ...

In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market

...e scrambling to understand the underlying causes and find new treatments. The availability and increased use of biologic treatments such as Enebrel, rituxan and Remicade, representing three-quarters of the RA market in 2006, has revived growth in the industry, offsetting declines for older non- steroidal a...

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

...gest that the administration of Specifid following rituxan may extend progression-free survival in patients w...in's lymphoma (NHL) compared to historical data of rituxan alone. In particular, 40% of the treatment-naive p...ws that approximately 20% of patients treated with rituxan alone were progression-free at three years. Most a...

Manufacturer to Pay $20 Million for Improperly Promoting a Sleep Disorder Drug

...gh the focus of the investigation is unclear, a lawsuit by a former Genentech employee has accused the firm and its partner, Biogen Idec, of promoting rituxan for rheumatoid arthritis before the FDA approved the drug for that purpose. In yet another local case, Gilead Sciences of Foster City disclose...
Rituxan in Medical Technology

InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies

- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with Novel Antibody and Speedy DXL Screening Preclinical Development Program - BRITISH COLUMBIA, Canada, Sept. 16 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.i...

Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Preliminary results were released today from a late-stage clinical trial of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of SLE (systemic lupus eryth...

Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update

...h RA. Pre-clinical research suggests that SBI- 087, a fully humanized CD20-directed SMIP, has enhanced potency in B-cell depletion in vivo compared to rituxan and other CD20-directed therapies. TRU-015 for RA In addition to SBI-087, Trubion also announced today the protocol details and design of the next...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

...oing commitment to developing oncology therapeutics and to helping patients with cancer." The 12 presentations include: -- Phase I/II Study of rituxan in Combination with DOXIL in Patients with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity - Myron S. Czuc...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...al of 349 patients were randomly assigned to receive either FavId plus Leukine(R) (sargramostim, GM-CSF) or placebo plus Leukine following a course of rituxan treatment. The primary endpoint of this trial is TTP. "As we previously communicated, the rate of progression in our pivotal Phase 3 trial has slowed...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

...cademy of Neurology annual meeting held in Boston. rituxan is a therapeutic antibody that targets and selecti...ed study that evaluated the safety and efficacy of rituxan in adult patients with RRMS, 104 patients were ran...zed to receive either a single treatment course of rituxan (two infusions separated by two weeks) or placebo....

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

... rituxan Significantly Reduced Signs of Disease Activity as...cademy of Neurology annual meeting held in Boston. rituxan is a therapeutic antibody that targets and selecti...ed study that evaluated the safety and efficacy of rituxan in adult patients with RRMS, 104 patients were ran...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

...al levels within several months. MabThera is indicated for the treatment of indolent and aggressive Non-Hodgkin's Lymphoma. MabThera is known as rituxan in the United States, Japan and Canada. To date, patients have received more than 1 million treatments with MabThera worldwide. Genentech and Bi...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

...normal levels within several months. MabThera is indicated for the treatment of indolent and aggressive Non-Hodgkin_s Lymphoma. MabThera is known as rituxan in the United States, Japan and Canada. To date, patients have received more than 1 million treatments with MabThera worldwide. Genentech and Biogen...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

...normal levels within several months. MabThera is indicated for the treatment of indolent and aggressive Non-Hodgkin's Lymphoma. MabThera is known as rituxan in the United States, Japan and Canada. To date, patients have received more than 1 million treatments with MabThera worldwide. Genentech and Biogen...
Rituxan in Biological News

Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells

... cells that are typically "invisible" to other antibodies because they express low levels of target antigen. "While antibodies such as Genentech's rituxan are well known for their role in the treatment of cancer, many other promising antibodies are sub-optimal for use as therapeutics. They just aren't po...

BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

... Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of...
Rituxan in Biological Technology

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

...responsible for all aspects of marketing and reimbursement. He was also a member of the management committee for the collaboration with Genentech on rituxan (R), a drug generating multi-billions of dollars annually and used for treating a number of cancer and autoimmune indications. As global head of busi...

Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?

...ty and tolerability concerns. Safety concerns with rituxan may continue with the recent news of the first fatal case of PML in a patient taking rituxan for RA. Most respondents indicated that Orencia is...osen after one TNF-alpha failure while Genentech's rituxan is reserved until patients have failed two or more...

CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market

... still the 9th in the top 10 biotech drugs sold in the US. The top 5 leading biotech drugs sold in the USA are Enbrel (Amgen, Wyeth), Aranesp (Amgen), rituxan (Biogen Idec, Genentech, Roche), Remicade (Johnson & Johnson, Schering-Plough) and Procrit (Johnson and Johnson). According to CBDMT®, con...

Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise

...d cardiology. As Vice President, Sales and Marketing for Genentech's Hematology Franchise, he led the commercial efforts for the top-selling biologic, rituxan (rituximab). Prior to joining Genentech in 2005, Mr. McRaith served with Abbott Laboratories for 15 years, where he held a number of senior positions ...

Biotech 2004: Cautious optimism

... Not all of these drugs will make it down the home stretch. 11. Finally, the sales success of new biotech drugs. Novartis Gleevec and Genentechs rituxan both were $1 billion drugs last year with the latter reaching sales of $2.1 billion and the former reaching sales of $1.1 billion. Both drugs happen t...
Rituxan in Biological Dictionary

Monoclonal antibodies

...dy Therapy in Lymphoid Malignancies ... CLL Topics - Patients dedicated to the fight against chronic lymphocytic ... The monoclonal antibodies rituxan and Campath have changed the landscape for CLL ... CLL Topics - Patients dedicated to the fight against chronic lymphocytic leukemia ... Related Ar...
Other Tags
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... The Preventer, a home patent that aims to protect ... , "House fires cost the United States a total ... and Creative Director of World Patent Marketing . ... homes that have no alarmed protection. With the use ...
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... the Hidee-Hose, an undergarment patent that allays women’s fears ... Women's Hosiery industry forecasts the market to reach $20.3 ... Creative Director of World Patent Marketing , "The ... ahead and is expected to maintain its lead. The ...
(Date:5/25/2015)... 2015 According to a recently published ... in hip external fixation market is driven by an ... and advancements in infection prevention technologies. As the population ... currently accounting for the largest total number of bone ... and accidents. As a result, the average selling price ...
(Date:5/25/2015)... Stanley Consultants has been ... of the wastewater treatment expansion at the ... National Recognition Award from the American Council of Engineering ... Iowa. Competitions held by the organization honor the ... expansion is Iowa City’s largest public works project ever. ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 ProDrop Light ... very own VJ neon light backdrops with a click of a ... scale and much more all within Final Cut Pro X. , ... categories such as drop zones, kaleidoscope and much more leaving infinite ... Light Show drop zones and text presets, users can apply ...
Breaking Medicine News(10 mins):Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2
(Date:5/21/2015)... , May 21, 2015 ... "Thermal Imaging Market by Solutions (Hardware, Software, Services), by ... Automotive & others), by End-Users (Military & Defense ... by MarketsandMarkets, Thermal Imaging Market is expected to ... Million by 2020, at a Compound Annual Growth ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
Other Contents